Single-molecule tracking at scale, analyzing millions of cells and thousands of compounds per day, demonstrates that measuring protein motion provides mechanistic insights relevant to drug discovery.

Formation of a giant unilocular vacuole through a macropinocytosis-like process in cells with disrupted actin cytoskeleton promotes resistance to anoikis.

Cryogenic electron microscopy enables real-time structure-based drug design to advance the discovery of novel classes of small molecule inhibitors.

eRNAs detected in patient-derived transcriptomic data can delineate potential active enhancer regions in oesophageal adenocarcinoma and uncover genes associated with the cancer phenotype.

Effective antiestrogens engage a new structural interaction to improve therapeutic antagonism in hormone-resistant breast cancer cells expressing Y537S estrogen receptor alpha.

The first-in-class kinase inhibitor, Ibrutinib, destabilizes its autoinhibited Bruton’s tyrosine kinase (BTK) target, and a remote resistance mutation causes global structural changes that activate BTK catalytic activity.

Human genomic DNA contains uracil in the late replicating, constitutive heterochromatic regions, while treatment with drugs perturbing thymidylate biosynthesis shifts the uracil distribution pattern towards the euchromatin in UNG-inhibited cells.

Bazedoxifene's SERD activities enable it to resist the impact of activating ESR1 mutations in breast cancer.